OncoMatch/Clinical Trials/NCT05691010
A Study of Short-Course Radiation Therapy With Chemotherapy in People With Endometrial Cancer
Is NCT05691010 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies multiple treatments including Carboplatin and Paclitaxel for endometrial cancer.
Treatment: Carboplatin · Paclitaxel — The purpose of this study is to find out whether short-course radiation therapy (1 week instead of the usual 5 weeks) with chemotherapy (carboplatin and paclitaxel) is practical (feasible), meaning that most participants are able to complete the treatment schedule.
Check if I qualifyExtracted eligibility criteria
Cancer type
Endometrial Cancer
Biomarker criteria
Excluded: MLH1 loss
Excluded: MSH2 loss
Excluded: MSH6 loss
Excluded: PMS2 loss
Excluded: POLE pathogenic mutation
Disease stage
Required: Stage FIGO (2009) IIIA, FIGO (2009) IIIC1 (FIGO (2009))
Patients must have FIGO (2009) stage IIIA or IIIC1 disease (as determined by surgical staging).
Performance status
KARNOFSKY OR ECOG 0–1
Karnofsky Performance Status (KPS) ≥ 70 (or ECOG 0 or 1)
Prior therapy
Must have received: surgery
Surgery must have included a hysterectomy, bilateral salpingo-oophorectomy, and pelvic lymph node surgical assessment (sentinel lymph node mapping and/or sampling). Para-aortic lymph node surgical assessment is optional.
Cannot have received: radiation therapy
No prior radiation therapy for treatment of endometrial cancer.
Cannot have received: chemotherapy
No prior chemotherapy for treatment of endometrial cancer.
Lab requirements
Blood counts
Absolute neutrophil count (ANC) ≥ 1500/mcL; Platelet count ≥ 100,000/mcL
Kidney function
Creatinine ≤ 1.5X ULN
Liver function
AST/ALT ≤ 3X upper limit of normal (ULN); Total bilirubin ≤ 1.5X ULN (≤ 3X ULN if Gilbert's disease)
Patients must have adequate organ function, defined by the following laboratory results no more than 14 days prior to first study treatment: * Absolute neutrophil count (ANC) ≥ 1500/mcL * Platelet count ≥ 100,000/mcL * AST/ALT ≤ 3X upper limit of normal (ULN) * Total bilirubin ≤ 1.5X ULN. Patients with known Gilbert's disease and a total bilirubin ≤ 3X ULN may be enrolled. * Creatinine ≤ 1.5X ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Memorial Sloan Kettering Basking Ridge (All protocol activities) · Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (All protocol activities) · Middletown, New Jersey
- Memorial Sloan Kettering Bergen (All protocol activities) · Montvale, New Jersey
- Memorial Sloan Kettering Commack (All protocol activities) · Commack, New York
- Memorial Sloan Kettering Westchester (All protocol activities) · Harrison, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify